Another gene therapy commands $1.8 million price tag

The price of Zynteglo, a new gene therapy made by Bluebird Bio, will be almost €1.6 million ($1.8 million) in Europe, the company said Friday. Bluebird expects to get FDA approval for Zynteglo next year and to price it similarly in the U.S., Reuters reports.

The big picture: Zynteglo becomes the second-most expensive drug in the world behind Zolgensma, the $2.1 million gene therapy made by Novartis.